Symbols

BRNS

Barinthus·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 2

Bearish signal 3

Consensus Rating "Strong Buy"

Ample Liquidity

Significant Revenue Decline

Significant Net Income Decline

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BRNS

Barinthus Biotherapeutics Plc

A clinical-stage biopharmaceutical company that develops immunotherapeutcs & vaccines for infectious diseases & cancer

Industry

Biological Technology

Established Date

Listing Date

04/30/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

105

Fiscal Year Ends

12-31

Website

www.barinthusbio.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

20400 Century Blvd Suite 210 Germantown MD 20874

Business

Introduction

Barinthus Biotherapeutics plc was incorporated in January 2016 under the laws of England and Wales. The company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel T-cell immunotherapy candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. The company has extensive clinical and preclinical stage treatment and prevention programs. The company's current treatment options include VTP-300 for the treatment of chronic hepatitis B infection, VTP-200 for the treatment of human papillomavirus infection, VTP-850 for the treatment of prostate cancer, VTP-600 for the treatment of non-small cell lung cancer, VTP-1000 for the treatment of celiac disease, and VTP-1100 for the treatment of HPV-related cancer. The latter two programs are designed to leverage the SNAPvaxTM platform. The company's current prevention programs include VTP-400 for the prevention of shingles or herpes zoster, and VTP-500 for the prevention of Middle East Respiratory Syndrome or MERS.

Company Financials

EPS

BRNS has released its 2025 Q3 earnings. EPS was reported at -0.36, versus the expected -0.4, beating expectations. The chart below visualizes how BRNS has performed over recent quarters, highlighting trends in earnings surprises.